Cargando…

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM

Detalles Bibliográficos
Autores principales:	Dierickx, Daan, Connerotte, Thierry, Dallemagne, Julie, Becker, Ann De, Moors, Ine, Snauwaert, Sylvia, Sonet, Anne, Theunissen, Koen, Breems, Dimitri, Prijck, Bernard De, Jaspers, Aurélie, Lambert, Catherine, Heyrman, Bert, Hautekiet, Joris, Lyna, Sofie, Maertens, Chantal, Delrieu, Vanessa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430097/ http://dx.doi.org/10.1097/01.HS9.0000973308.93798.cb

Ejemplares similares

Caplacizumab as frontline therapy in addition to standard treatment in iTTP
por: Cid, Joan, et al.
Publicado: (2022)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase
por: Westwood, John Paul, et al.
Publicado: (2022)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020)

Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab
por: Mellaza, Chloé, et al.
Publicado: (2020)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

Post Approval Experience with Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura at a Single Institution
por: Logothetis, Constantine N., et al.
Publicado: (2021)

Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
por: Bergstrand, Martin, et al.
Publicado: (2021)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022)

Brazilian experience with caplacizumab in acquired thrombotic thrombocytopenic purpura: outcomes of the expanded access program
por: de Oliveira Boechat, Tiago, et al.
Publicado: (2023)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection
por: Fang, Fei, et al.
Publicado: (2022)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020)

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
por: Djulbegovic, Mia, et al.
Publicado: (2022)

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Campaña contra Yanga en 1608.
por: Laurencio, Juan B.
Publicado: (1974)

Catálogo de documentos coloniales, 1608-1810 /
Publicado: (1993)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
por: Cardesa‐Salzmann, Teresa Marta, et al.
Publicado: (2022)

Caplacizumab: First Global Approval
por: Duggan, Sean
Publicado: (2018)

Unmet needs in the management of immune‐mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UK—A modified‐Delphi study
por: Scully, Marie, et al.
Publicado: (2022)

The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
por: Miyakawa, Yoshitaka, et al.
Publicado: (2022)

Correction to: Caplacizumab: First Global Approval
por: Duggan, Sean
Publicado: (2018)

Caplacizumab: frequent local skin reactions
por: Kaufeld, Jessica, et al.
Publicado: (2020)

P1608: EXPERIENCE AND COMPLICATIONS WITH THE USE OF PICCS IN HEMATOLOGIC PATIENTS
por: Sanchez-Paz, L., et al.
Publicado: (2022)

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study
por: Scully, Marie, et al.
Publicado: (2022)

Catálogo de documentos coloniales, 1608-1810 : Archivo histórico de la Ciudad de Veracruz
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_tbkqdts2enuhioips6i97399ra